Lu and colleagues identify BRD4 as a central epigenetic driver of vesicant-induced corneal injury. Using reproducible mouse and rabbit models, they show that short-term topical BRD4 inhibition suppresses acute inflammation and provides durable protection of corneal clarity, stromal organization, endothelial integrity, and neovascularization, supporting translational therapy for chemical eye injuries.

Ouabain triggers cochlear spiral ganglion neuron (SGN) ferroptosis and hearing loss via SCD1 downregulation. MITF directly activates Scd1 transcription, and the MITF–SCD1 axis mitigates SGN ferroptosis and hearing impairment in ototoxic ouabain and cisplatin models, revealing a lipid metabolic vulnerability and therapeutic target for sensorineural hearing loss.